Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...

Nearly half of all new cases in 2022 were in the South. "The frustrating part is we have the tools now to stop it." ...

Already, significant harm has been done to inhibit progress combating HIV/AIDS, and the next four years could return us to ...

The Conference on Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

During the opening day of the Conference on Retroviruses and Opportunistic Infections, Rebecca Denison, a decades-long HIV ...

A generation has passed since the world saw the peak in AIDS-related deaths. Those deaths—agonizing, from diseases or infections the body might otherwise fight off—sent loved ones into the streets, ...

The advent of effective antiretroviral therapy (ART) has increased the lifespan of many people living with HIV. As a result, ...

Debates over tuberculosis reporting began in the late 19th century, when the bacterial infection was reframed not as a disease of the elite but of the urban poor. New York City was the first in the ...

Millions of people worldwide are likely to lose access to anti HIV drugs, and thousands more people could die, after the US ...